| Effects of thalidomide treatment in heart failure patients. | |
| | |
MedLine Citation:
|
PMID: 17106197 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Several studies have reported a direct association between elevated plasma levels of inflammatory cytokines and worse functional class (New York Heart Association [NYHA]) and cardiac function, measured as left ventricular ejection fraction (LVEF). Thalidomide has recently shown to improve LVEF in chronic heart failure patients, accompanied by a marked decrease in plasma levels of tumor necrosis factor alpha (TNF-alpha). METHODS: In a randomized prospective open label study of men and women with heart failure (HF) due to ischemic and non-ischemic cardiomyopathy who had systolic dysfunction (LVEF <40%) and NHYA classification, functional classes II and III were assigned to control (without thalidomide, 60 patients) or thalidomide group (20 patients). The initial dose of thalidomide was 100 mg once a day, and it was increased to 100 mg twice a day after a period of 10 days, if the prior dosage was well-tolerated. Demographic characteristics, etiology of HF, prior myocardial infarction, co-morbidities associated were registered and laboratory routine test, TNF-alpha serum levels, and echocardiogram were obtained at the beginning and after 6 months of follow-up. RESULTS: Clinical status (NYHA) at the end of the follow-up period, improved moderately in both groups. TNF-alpha levels were initially of 5.88 +/- 0.9 and 6.49 +/- 1.82 vs. 6.32 +/- 1.6 and 7.94 +/- 3.8 pg/ml during follow-up, for thalidomide and control groups, respectively. There were non-significant differences in echocardiography variables. CONCLUSION: In conclusion, although there is a large amount of information supporting a direct relationship between TNF-alpha and worsening of symptoms and prognosis in patients with HF and recently, the beneficial effect on thalidomide treatment has been suggested, these preliminary observations should be confirmed in a larger prospective study, specially trying to clarify the action mechanisms. |
| | |
Authors:
|
Arturo Orea-Tejeda; Oscar Arrieta-Rodríguez; Lilia Castillo-Martínez; Tatiana Rodríguez-Reyna; Enrique Asensio-Lafuente; Julio Granados-Arriola; Joel Dorantes-García |
Related Documents
:
|
12701987 - Using bnp to diagnose, manage, and treat heart failure. 20662867 - Uric acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparis... 16008547 - Use of pro-atrial natriuretic peptide in the detection of myocardial ischaemia. 8164337 - Changes in the circulating endothelin and atrial natriuretic peptide levels during coro... 20513067 - Progression of coronary artery disease during long-term follow-up of the swiss interven... 1706857 - Implantable pharmacological defibrillator (aiphd): preliminary investigations in animals. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2006-11-09 |
Journal Detail:
|
Title: Cardiology Volume: 108 ISSN: 1421-9751 ISO Abbreviation: Cardiology Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-11-16 Completed Date: 2008-01-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1266406 Medline TA: Cardiology Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 237-42 Citation Subset: IM |
Copyright Information:
|
(c) 2007 S. Karger AG, Basel. |
Affiliation:
|
Heart Failure Clinic, México City, Mexico. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Biological Markers / blood Cardiovascular Agents / therapeutic use* Female Heart Failure / blood, drug therapy* Humans Male Middle Aged Prospective Studies Thalidomide / therapeutic use* Tumor Necrosis Factor-alpha / blood |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cardiovascular Agents; 0/Tumor Necrosis Factor-alpha; 50-35-1/Thalidomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat mode...
Next Document: Leakage of colon anastomoses: development of an experimental model in pigs.